PSPA 31 - Patient Medication Risk Education

Activity Weighting: High

Subcategory Name: Patient Safety and Practice Assessment

Description: In order to receive credit for this activity, MIPS eligible clinicians must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids. 

Supporting Documentation

Education must be completed for at least 75% of qualifying patients and occur:

  • at the time of initial co-prescribing and again following greater than 6 months of co- prescribing of benzodiazepines and opioids, or 
  • at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.

Resources

2018 Improvement Activities Requirements

2019 Improvement Activities Requirements

2018 MIPS Improvement Activities Fact Sheet

Scores for Improvement Activities for MIPS APMs in the 2018 Performance Period Fact Sheet

WebChart Documentation
Last Build: Wed, 08 Sep 2021 00:25:58 EDT Legacy Documentation